Aurora UK Alpha PLC Reports 2024 Performance and Strategic Merger
Alpha HPA's AU$182m Market Cap Fall Books Insider Losses
Alpha Group Executes Share Buyback to Enhance Shareholder Value
Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress
Puma Alpha VCT Announces Further Share Allotment
Aurora UK Alpha Plc Releases March 2025 Fact Sheet
Alpha Data Renews Business License in UAE
Alpha Buying: Unpacking the Power of Activist Investors in Driving Company Performance
Alpha FMC Releases 2025 Asset & Wealth Management and Alternatives Outlooks: AI, Private Markets, and Regulatory Shifts Take Center Stage
Alpha Tau Granted FDA Approval To Initiate Trial For Patients With Recurrent Glioblastoma
Alpha Growth Executives Increase Stake in Company
The Bridgewater flagship Fund Pure Alpha achieved an ROI of 9.9% in the first quarter with the motto "Don't aim to be the biggest, but the best."
Bridgewater Associates, the world's largest hedge fund, achieved a 9.9% ROI in the first quarter of this year, despite a reported 18.1% decline in assets under management after the company reduced its scale to better explore Trade opportunities last year. An informed source revealed that Bridgewater's Pure Alpha fund, which has an 18% volatility, experienced an increase due to market concerns over the Trump administration's trade policies. The fund increased by 11.3% in 2024, outperforming Industry levels. However, Bridgewater reported in documents submitted on March 28 that
Alpha Bank Upgraded to 'BB+' by Fitch With Positive Outlook
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024
Is Alpha Technology Group Ltd. (ATGL) the Best Performing NASDAQ Stock So Far in 2025?
Express News | Alpha Capital Anstalt-Website at Alphacapitals.com Is Not a Legitimate Website of Co
Alpha Capital Anstalt Issues Scam and Fraud Alert Update
Express News | Airna Raises Oversubscribed $155 Million Series B Financing to Fund Phase 1/2 Clinical Trial for Alpha-1 Antitrypsin Deficiency and Future Pipeline
Alpha Group Executes Share Buyback, Adjusts Voting Rights
Earnings Call Summary | Alpha Cognition(ACOG.US) Q4 2024 Earnings Conference